Bill · S. 998· Senate(119-S-998)
Medical Supply Chain Resiliency Act
- Introduced
- 3/12/2025
- Last activity
- 3/12/2025 — Read twice and referred to the Committee on Finance.
- Sponsored by
- Thomas Tillis
- Cosponsors
- - 1 - 2
- Introduced
- In Committee
What this bill would do
The Medical Supply Chain Resiliency Act aims to authorize the President to enter into trade agreements with trusted partners to improve the security of medical goods. This legislation seeks to diversify supplier networks to prevent shortages seen during the COVID-19 pandemic. It provides a framework for the reciprocal elimination of duties and import restrictions on medical devices and pharmaceuticals. The bill focuses on enhancing supply chain security through regulatory cooperation and intellectual property protection. Additionally, it establishes oversight mechanisms for Congress to review and potentially disapprove these trade agreements.
Yes· 3 of 13
Does this make the country readier for the next outbreak?+8
The bill specifically targets strengthening supply chains to prepare for future public health emergencies.
Does this make trade with other countries easier?+7
The bill facilitates more efficient trade by reducing duties and regulatory barriers for medical goods.
Does this strengthen ties with allied countries?+6
The bill focuses on establishing and strengthening trade relationships with trusted international partners.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Improved Supply Chain Security: The bill aims to diversify and expand supplier networks to ensure a reliable supply of medical goods, particularly during emergency situations. (Section 3, Purpose 2 and 3)
-
Reduced Trade Barriers: It seeks to eliminate unnecessary trade barriers and distortions that can disrupt or weaken medical supply chains. (Section s 3, Purpose 4)
-
Faster Movement of Goods: The act intends to expedite the cross-border movement of critical medical goods. (Section 3, Purpose 5)
-
Increased Research and Development: The framework promotes international collaboration and encourages new investments in research and development for medical goods. (Section 3, Purpose 6)
-
Enhanced Regulatory Efficiency: By promoting regulatory cooperation and the adoption of good regulatory practices, the bill aims to streamline the movement of medical devices and pharmaceutical goods. (Section 3, Purpose 7 and 10)
Potential Negative Impacts for People
- Risk of Economic Disincentives: The bill notes that duties and trade barriers can exist to prevent disincentivizing research, development, and manufacturing within the United States. (Section 5, Subsection c, Paragraph 1)
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Healthcare
- Improves Pandemic Preparedness+8Improves Healthcare Access+5Increases Research Funding+4
- National Security And Foreign Policy
- Improves International Trade+7Improves International Alliances+6Improves Diplomatic Engagement+4
- Governance And Ideology
- Improves Government Transparency+5Increases Federal Power+4
- Education And Technology
- Improves Intellectual Property Fairness+5Increases Scientific Research Funding+3
- Demographic And Interest Groups
- Good For Business Owners+4
- Environment Energy And Infrastructure
- Improves Disaster Relief And F E M A+4
- Economy And Finance
- Improves Consumer Protection+3
- 3/12/2025
- Read twice and referred to the Committee on Finance.
- 3 Cosponsors added.
- Introduced in Senate
One bill Congress.gov lists as related to this one — companions in the other chamber, earlier versions, and bills this one absorbed or was folded into.
Michael BennetDemocrat · Colorado
John CornynRepublican · Texas
Christopher CoonsDemocrat · Delaware